Gordon Cook is a graduate of the University of Glasgow School of Medicine and received his higher professional training in haematology in the West of Scotland. After completing his PhD, Professor Cook was appointed as a Consultant Haematologist in the West of Scotland before moving to take up the post of Director of Stem Cell Transplantation at Leeds Teaching Hospitals in 2002. In 2013 he was appointed as Professor of Haematology, University of Leeds where he leads the myeloma clinical and translational research portfolio with a primary interest in tumour immunology and immunotherapy.
He established and was the first Chair of the UK Myeloma Research Alliance, having stepped down in 2019. Professor Cook is the past-chair of the UK Myeloma Forum and has established the College of Myeloma (UK) which elected its first fellows in 2019. He has represented the interests of both myeloma clinicians and patients in National Institute of Clinical care & Excellence reviews and technology appraisals and is a current committee member of the NHS England Chemotherapy CRG.
Professor Cook has developed and delivered an extensive national clinical research portfolio. Currently, he is Chief Investigator for NCRI Myeloma X (completed), UKMRA Myeloma XII (in recruitment), UKMRA Myeloma XIV (in recruitment), MUKeight (completed) and MUKeleven (finished). His collaboration with industry includes his position as the UK Chief investigator for 5 industry international phase III and IIIb studies.
He holds the posts of Clinical Director of National Institute of Health Research (Leeds) Medtech & In Vitro Diagnostics Cooperative and Clinical Director (Haematology), Clinical Trials Research Unit, University of Leeds.EM-59965 - Date of preparation: April 2021